Liarozol
Nazivi | |
---|---|
IUPAC naziv 6-[(3-hlorofenil)-imidazol-1-ilmetil]-1H-benzimidazol | |
Identifikacija | |
| |
3D model (Jmol) |
|
ChemSpider |
|
IUPHAR/BPS |
|
PubChem[1][2] C ID |
|
SMILES
| |
Svojstva | |
C17H13ClN4 | |
Molarna masa | 308,77 g·mol−1 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
Reference infokutije | |
Liarozol je jedinjenje koje inhibira metabolizam retinoinske kiseline.[3]
Sinteza
Reference
- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Vahlquist, A; Blockhuys, S; Steijlen, P; Van Rossem, K; Didona, B; Blanco, D; Traupe, H (2013). „Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: Results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial”. The British journal of dermatology. 170 (1): n/a. PMID 24102348. doi:10.1111/bjd.12626.